Researchers Announce TB Vaccine M72 Ready for Teens and Adults

SEAToday.com, Jakarta - Indonesia is progressing with the tuberculosis (TB) vaccine M72/AS01E, aimed at protecting adolescents and adults. National TB Vaccine Researcher Prof. Dr. Erlina Burhan, Sp.P(K), stated that phase three clinical trials are underway after phase 2B trials showed a 50% efficacy rate.

"We hope to complete recruitment by early April and follow participants for three years. By 2028, we should have results and, hopefully, begin production," said Dr. Erlina as quoted on Antara.

This vaccine is a breakthrough since BCG, which only protects infants. WHO's "Global Tuberculosis Report 2024" reported 10.8 million TB cases globally in 2023, with Indonesia ranking second at 1,090,000 cases and 130,000 deaths.

"In phase 2, efficacy was 50-54%. With more participants in phase 3, we hope for even better results. WHO considers over 50% efficacy effective," she added as quoted on Antara.

Indonesia’s research is part of a global study with South Africa, Kenya, Zambia, and Malawi. In late 2022, Indonesia finalized protocols and secured five research sites: UI and Padjadjaran University’s medical faculties, Persahabatan General Hospital, UI Hospital, and Jakarta Islamic Hospital Cempaka Putih.

By March 6, 2025, 1,839 participants had been enrolled, receiving two doses a month apart. Mild post-vaccine reactions, such as fever and pain, have been managed effectively.

Dr. Erlina urged Indonesians to maintain a healthy lifestyle while awaiting the vaccine. "We must optimize existing TB programs while waiting for the vaccine in 2028," she concluded as quoted on Antara.

Writer: Andi Raisa Malaha Thambas